LUMIGAN 054: A 2-year, multicenter, double-masked, randomized, parallel study of the safety of LUMIGAN® 0.1 mg/mL compared with LUMIGAN® 0.3 mg/mL in patients with glaucoma or ocular hypertension
Laufzeit: 01.01.2011 - 31.12.2015
imported
Kurzfassung
A 2-year, multicenter, double-masked, randomized, parallel study of the safety of LUMIGAN 0.1 mg/mL compared with LUMIGAN 0.3 mg/mL in patients with glaucoma or ocular hypertension
